Daily Medication Pearl: Atezolizumab (Tecentriq)
Atezolizumab (Tecentriq) is indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
Medication Pearl of the Day: Atezolizumab (Tecentriq)
Indication: Atezolizumab (Tecentriq) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
- Dosing:Administer atezolizumab intravenously over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
- Dosage forms: Injection: 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial.
- Adverse events:Most common adverse reactions (≥ 20%) with atezolizumab as a single agent were fatigue/asthenia, decreased appetite, nausea, cough, and dyspnea.
- Mechanism of action: PD-L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production
- Manufacturer: Genentech